Growth hormone prevents human immunodeficiency virus–induced neuronal p53 expression
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Growth hormone (GH) is neuroprotective, presumably through its actions on GH receptor–mediated pathways. Here, we examined the effects of GH using in vitro and in vivo assays of human immunodeficiency virus (HIV)–induced neuronal injury. Neuronal cultures were in assays of neurotoxicity induced by supernatants from HIV‐1 tat‐transfected monocytoid cells (Tat supernatant). GH treatment reduced neuronal death compared with untreated cultures (p < 0.001), which was blocked by a GH receptor antagonist, B2036. Tat supernatant–induced p53 expression in neurons was also reduced by GH treatment. Expression of both p53 and GH receptor were increased in brain tissue from HIV‐infected persons compared with controls (p < 0.05). Mice receiving intrastriatal implants of Tat supernatant and treated with GH showed less neurobehavioral abnormalities together with reduced neuroinflammation and neuronal injury compared with untreated animals (p < 0.01). Three acquired immunodeficiency syndrome–defined patients with neurocognitive impairment were serially evaluated during daily GH treatment showing a sustained improvement in neuropsychological performance (p < 0.01). GH prevents neuronal death through its actions on neurons involving a p53‐mediated pathway and also improved in vivo neurological function, indicating that GH may have a role in the treatment of HIV‐induced neurodegeneration. Ann Neurol 2003;54:605–614
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased mortality associated with growth hormone treatment in critically ill adults
Takala, J., Ruokonen, E., Webster, N. R., Nielsen, M. S., Zandstra, D. F., Vundelinckx, G., & Hinds, C. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411102 · Cited by 1,023
Imai, Y., Ibata, I., Ito, D., Ohsawa, K., & Kohsaka, S. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1112 · Cited by 872 · cited 1×
“Imai, National Center of Neurology and Psychiatry, Japan), as previously reported.(25) Counts of immunopositive cells adjacent to, but not including, the site of striatal implantation were performed and reported as cells per high-power field (1.”
BackgroundGrowth hormone as a neuronal rescue factor during recovery from CNS injury
Scheepens, A., Sirimanne, E. S., Breier, B. H., Clark, R. G., Gluckman, P. D., & Williams, C. E. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00109-9 · Cited by 174 · cited 1×
“GH also induces insulin-like growth factor (IGF)–1, an established neuroprotective molecule, which may subserve GH’s neuroprotective effects in spinal cord injury and cerebral ischemia.(14,21) In this study, we examined the effects of GH as a neuroprotective compound in vitro and in vivo, which showed it reduced neuro…”
BackgroundScheepens, A., Williams, C. E., Breier, B. Η., Guan, J., & Gluckman, P. D. (2000) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2000-s623 · Cited by 82 · cited 1×
“Alternatively, its effects might be mediated through regulation of somatostatin levels.(16) GH also induces insulin-like growth factor (IGF)–1, an established neuroprotective molecule, which may subserve GH’s neuroprotective effects in spinal cord injury and cerebral ischemia.”
Background
Cited by
Growth hormone (GH) and brain trauma
Devesa, J., Reimunde, P., Devesa, P., Barberá, M., & Arce, V. (2013) · Hormones and Behavior · doi:10.1016/j.yhbeh.2012.02.022 · Cited by 87
Arce, V. M., Devesa, P., & Devesa, J. (2013) · Neuroscience Research · doi:10.1016/j.neures.2013.03.014 · Cited by 70
Metadata
- Authors
- Silva, C., Zhang, K., Tsutsui, S., Holden, J. K., Gill, M. J., & Power, C.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2003-10-22
- Volume
- 54
- Issue
- 5
- Pages
- 605-614
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1985855615
- Cited by
- 57
- References
- 4
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.